Analysts forecast that Affimed N.V. (NASDAQ:AFMD) will report earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Three analysts have issued estimates for Affimed N.V.’s earnings, with estimates ranging from ($0.23) to ($0.19). Affimed N.V. reported earnings per share of ($0.35) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40%. The company is scheduled to issue its next earnings results on Wednesday, November 1st.
On average, analysts expect that Affimed N.V. will report full year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.86) to ($0.74). For the next financial year, analysts forecast that the company will report earnings of ($0.70) per share, with EPS estimates ranging from ($0.85) to ($0.54). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Affimed N.V..
Affimed N.V. (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The business had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $1.31 million. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The business’s quarterly revenue was down 75.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.24) earnings per share.
AFMD has been the subject of several recent analyst reports. Oppenheimer Holdings, Inc. set a $10.00 price target on Affimed N.V. and gave the company a “buy” rating in a research note on Saturday, April 15th. Zacks Investment Research upgraded Affimed N.V. from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Wednesday, April 19th. Jefferies Group LLC lifted their price objective on Affimed N.V. to $2.50 and gave the stock a “hold” rating in a report on Wednesday, April 26th. ValuEngine upgraded Affimed N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. initiated coverage on Affimed N.V. in a report on Thursday, July 13th. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $4.80.
A number of large investors have recently bought and sold shares of AFMD. Creative Planning boosted its stake in Affimed N.V. by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 15,000 shares during the last quarter. Nationwide Fund Advisors boosted its stake in Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 479,007 shares during the last quarter. NEA Management Company LLC purchased a new stake in Affimed N.V. during the first quarter valued at about $8,944,000. Wellington Management Group LLP boosted its stake in Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 1,274,852 shares during the last quarter. Finally, Tekla Capital Management LLC boosted its stake in Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock valued at $3,232,000 after buying an additional 1,111,111 shares during the last quarter. Institutional investors own 42.41% of the company’s stock.
Shares of Affimed N.V. (NASDAQ:AFMD) traded down 2.33% during mid-day trading on Friday, reaching $2.10. The company’s stock had a trading volume of 150,411 shares. The firm’s market cap is $92.27 million. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $3.23. The firm’s 50-day moving average price is $2.23 and its 200 day moving average price is $2.23.
ILLEGAL ACTIVITY NOTICE: “Affimed N.V. (NASDAQ:AFMD) Expected to Announce Earnings of -$0.21 Per Share” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/affimed-n-v-nasdaqafmd-expected-to-announce-earnings-of-0-21-per-share-updated.html.
About Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.